Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis
N Engl J Med 2016;375:345–56. doi: 10.1056/NEJMoa1512711
Gordon, et al. pool the results of UNCOVER-1, UNCOVER-2, and UNCOVER-3 to show that ixekizumab increases the proportion of patients achieving an sPGA score of 0/1 or PASI 75 versus placebo. Adverse events related to ixekizumab treatment included neutropenia, candidal infections, and inflammatory bowel disease.
UNCOVER-1, UNCOVER-2, and UNCOVER-3 were three multicentre, placebo-controlled Phase 3 RCTs that were conducted across 100 sites worldwide. Patients in UNCOVER-1 were randomised 1:1:1 to placebo, ixekizumab 80mg Q2W, or ixekizumab 80mg Q4W, while patients in UNCOVER-2 and UNCOVER-3 were randomised 1:2:2:2 to include a 4th arm with patients receiving 50mg etanercept twice weekly.
Keywords:
